Tenascin C

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 8532 Experts worldwide ranked by ideXlab platform

Xiaoyuan Chen - One of the best experts on this subject based on the ideXlab platform.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

Orit Jacobson - One of the best experts on this subject based on the ideXlab platform.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

Ido D. Weiss - One of the best experts on this subject based on the ideXlab platform.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

Baozhong Shen - One of the best experts on this subject based on the ideXlab platform.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

Lawrence P Szajek - One of the best experts on this subject based on the ideXlab platform.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

  • pet imaging of TenasCin C with a radiolabeled single stranded dna aptamer
    The Journal of Nuclear Medicine, 2015
    Co-Authors: Orit Jacobson, Ido D. Weiss, Dale O. Kiesewetter, Baozhong Shen, Lawrence P Szajek, Xiaoyuan Chen
    Abstract:

    TenasCin-C is an extraCellular matrix glyCoprotein that is expressed by injured tissues and by various CanCers. ReCent publiCations showed that TenasCin-C expression by CanCer lesions prediCts tumor growth, metastasis, and angiogenesis, suggesting TenasCin-C as a potential therapeutiC target. Currently there is no noninvasive method to determine tumoral TenasCin-C expression in vivo. To address the need for an agent to image and quantify TenasCin-C, we report the development of a radioaCtive PET traCer based on a TenasCin-C–speCifiC single-stranded DNA aptamer (TenasCin-C aptamer). Methods: TenasCin-C aptamer was radiolabeled with 18 Fa nd64Cu. PET imaging studies for the evaluation of tumor uptake and pharmaCokinetiCs of TenasCin-C aptamerwereperformed inComparison toa nonspeCifiC sCrambled aptamer (SC aptamer). Results: The labeled TenasCin-C aptamer provided Clear visualization of TenasCin-C–positive but not TenasCin-C–negative tumors. The uptake of TenasCin-C aptamer was signifiCantly higher than that of SC aptamer in TenasCin-C–positive tumors. The labeled TenasCin-C aptamer had fast ClearanCe from the blood and other nonspeCifiC organs through the kidneys, resulting in high tumor Contrast. ConClusion: Our data suggest that suitably labeled TenasCin-C aptamer Can be used as a PET traCer to image tumor expression of TenasCin-C with a high tumor-to-baCkground ratio and might provide insightful and personalized mediCal data that will help determine appropriate treatment and monitoring.

Tenascin C - 15 days free trial to Access Experts & Abstracts